Cargando…
Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis
In systemic mastocytosis (SM), the clinical features and survival vary greatly. Patient-related factors determining the outcome in SM are largely unknown. Methods: We examined the impact of sex on the clinical features, progression-free survival (PFS), and overall survival (OS) in 3403 patients with...
Ejemplares similares
-
Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry
por: Kennedy, Vanessa E., et al.
Publicado: (2022) -
Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions
por: Valent, Peter, et al.
Publicado: (2020) -
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal
por: Valent, Peter, et al.
Publicado: (2021) -
Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022
por: Valent, Peter, et al.
Publicado: (2022) -
COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)
por: Bonadonna, Patrizia, et al.
Publicado: (2021)